ArticleFrontiers in pharmacology2025
Case Report: Omalizumab combined with voriconazole for the treatment of ABPA complicating IPA: a case report.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biologic switching in allergic bronchopulmonary aspergillosis: a scoping review of published clinical experience.Journal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillus invading hosts may manifest as Allergic bronchopulmonary aspergillosis (ABPA) or invasive pulmonary aspergillosis (IPA) in individuals with varying immune statuses. ABPA predominantly occurs in severe asthma patients, whereas IPA is typically observed in immunocompromised individuals. ABPA management centers on glucocorticoids to mitigate hypersensitivity-driven inflammation, while IPA requires aggressive antifungal therapy. Concurrent ABPA and IPA presents a therapeutic dilemma, as glucocorticoids use may exacerbate fungal dissemination, while antifungal agents alone inadequately address the allergic component. Adjusting treatment strategies to balance immunosuppression to control ABPA with sufficient antifungal coverage for IPA is critical step. The case report presents an innovative therapeutic strategy for a 73-year-old female with co-existing ABPA and IPA. After suboptimal clinical response to conventional glucocorticoid-antifungal therapy, we implemented a guideline-aligned, evidence-based regimen combining omalizumab with voriconazole. While this dual therapy achieved clinical stabilization, persistently elevated serum IgE (>5000 IU/mL). By reviewing the literature and comparing the differences between the mechanisms of omalizumab and dupilumab, the treatment was finally changed from omalizumab to dupilumab and followed up. This case is also a practice guided by ISHAM guidelines while pioneering a mechanism-driven transition from omalizumab to dupilumab in ABPA-IPA co-management. In order to provide guidance for the treatment of ABPA-IPA disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.